From: Usage of skin care products and risk of rheumatoid arthritis: results from the Swedish EIRA study
Anti-CCP-positive RA | Anti-CCP-negative RA | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Exposure | Number of exposed cases/controlsa | RRb | 95% CI | RRc | 95% CI | Number of exposed cases/controlsa | RRb | 95% CI | RRc | 95% CI |
Women | ||||||||||
A | 65/118 | 1.0 | Reference | 1.0 | Reference | 38/118 | 1.0 | Reference | 1.0 | Reference |
B | 110/174 | 1.1 | 0.7 to 1.7 | 1.0 | 0.7 to 1.6 | 68/174 | 1.2 | 0.7 to 1.9 | 1.1 | 0.6 to 1.9 |
C | 106/230 | 0.8 | 0.6 to 1.2 | 0.8 | 0.5 to 1.2 | 68/230 | 0.9 | 0.6 to 1.5 | 0.9 | 0.5 to 1.5 |
D | 199/370 | 0.9 | 0.6 to 1.3 | 0.8 | 0.6 to 1.2 | 116/370 | 0.9 | 0.6 to 1.4 | 0.9 | 0.6 to 1.4 |
E | 130/294 | 0.7 | 0.5 to 1.1 | 0.7 | 0.4 to 1.0 | 100/294 | 1.0 | 0.6 to 1.6 | 0.9 | 0.5 to 1.5 |
Men | ||||||||||
A | 197/359 | 1.0 | Reference | 1.0 | Reference | 113/359 | 1.0 | Reference | 1.0 | Reference |
B | 27/78 | 0.6 | 0.4 to 1.0 | 0.6 | 0.3 to 1.0 | 25/78 | 1.0 | 0.6 to 1.6 | 1.1 | 0.6 to 1.8 |
C | 12/27 | 0.7 | 0.3 to 1.4 | 0.7 | 0.3 to 1.4 | 10/27 | 1.1 | 0.5 to 2.5 | 1.2 | 0.6 to 2.8 |
D | 7/13 | 1.1 | 0.4 to 2.9 | 1.1 | 0.4 to 3.0 | 5/13 | 1.3 | 0.4 to 3.7 | 1.2 | 0.4 to 3.6 |
E | 4/6 | 1.3 | 0.3 to 4.7 | 0.9 | 0.2 to 3.8 | 0/6 | n.a. | n.a. | n.a | n.a. |
All | ||||||||||
A | 162/477 | 1.0 | Reference | 1.0 | Reference | 151/477 | 1.0 | Reference | 1.0 | Reference |
B | 137/252 | 0.9 | 0.6 to 1.2 | 0.8 | 0.6 to 1.1 | 93/252 | 1.1 | 0.7 to 1.5 | 1.0 | 0.7 to 1.5 |
C | 118/257 | 0.8 | 0.6 to 1.1 | 0.7 | 0.5 to 1.1 | 78/257 | 1.0 | 0.6 to 1.4 | 0.9 | 0.6 to 1.4 |
D | 206/383 | 0.9 | 0.7 to 1.3 | 0.9 | 0.6 to 1.2 | 121/383 | 0.9 | 0.6 to 1.4 | 0.9 | 0.6 to 1.4 |
E | 134/300 | 0.8 | 0.6 to 1.1 | 0.7 | 0.5 to 1.0 | 100/300 | 0.9 | 0.6 to 1.4 | 0.8 | 0.5 to 1.3 |